Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 5/20 | 0.73 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.56 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 8-Aminoguanine SCHEMBL5513824 | 0.98 | PNP (0.77) | PNPFGFR1FGFR2KDM4EMEN1 | |
| 8-Aminoguanine SCHEMBL21761 | 0.85 | PNP (1.00) | PNPFGFR1FGFR2KDM4EMEN1 | |
| SCHEMBL19461404 | 0.80 | PNP (0.47) | PNPFGFR1FGFR2KDM4EMEN1 | |
| SCHEMBL22883 | 0.76 | PNP (0.73) | PNPFGFR1FGFR2KDM4EMEN1 | |
| SCHEMBL20577 | 0.76 | PNP (0.73) | PNPFGFR1FGFR2KDM4EMEN1 | |
| SCHEMBL843932 | 0.76 | PNP (0.73) | PNPFGFR1FGFR2KDM4EMEN1 | |
| SCHEMBL844207 | 0.76 | PNP (0.73) | PNPFGFR1FGFR2KDM4EMEN1 | |
| SCHEMBL9116 | 0.76 | PNP (0.73) | PNPFGFR1FGFR2KDM4EMEN1 | |
| SCHEMBL6686388 | 0.76 | PNP (0.73) | PNPFGFR1FGFR2KDM4EMEN1 | |
| SCHEMBL2051361 | 0.76 | PNP (0.73) | PNPFGFR1FGFR2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5482 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630827-B2 | Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies | ROGCON, INC. (US) | 2026-05-19 | — | — | US | claimed |
| US-20250295658-A1 | ANTIPARASITIC AGENTS AND METHODS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2025-09-25 | — | — | US | claimed |
| US-20250257360-A1 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | UNIV OKLAHOMA (US) | 2025-08-14 | — | — | US | claimed |
| CN-113151261-B | Antisense oligonucleotides as inhibitors of TGF-R signaling | 神经视觉医药有限公司 | 2025-06-17 | — | — | CN | claimed |
| US-20250179503-A1 | METHODS OF USING OLIGOMERIC COMPOUNDS TO TREAT SCN2A-RELATED DISORDERS | PRAXIS PREC MEDICINES INC (US) | 2025-06-05 | — | — | US | claimed |
| US-20250146073-A1 | METHODS FOR THE TREATMENT OF SCN2A-RELATED DISORDERS | PRAXIS PREC MEDICINES INC (US) | 2025-05-08 | — | — | US | claimed |
| EP-4549577-A1 | NOVEL INDUCED CYTOPLASMIC IVT (ICIVT)-LIKE COMPOSITION AND THE RELATED VACCINE MEDICINE DESIGNS THEREOF | Mello Biotech Taiwan Co., Ltd. (TW) | 2025-05-07 | — | — | EP | claimed |
| US-20250115932-A1 | INDUCED CYTOPLASMIC IVT (ICIVT)-LIKE COMPOSITION AND THE RELATED VACCINE MEDICINE DESIGNS THEREOF | MELLO BIOTECH TAIWAN CO., LTD. (TW) | 2025-04-10 | — | — | US | claimed |
| EP-4506456-A1 | NOVEL OXO-RNA COMPOSITIONS AND THE RELATED APPLICATIONS THEREOF | Lin, Shi-Lung (US) | 2025-02-12 | — | — | EP | claimed |
| EP-4504945-A2 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | The Board of Regents of the University of Oklahoma (US) | 2025-02-12 | — | — | EP | claimed |
| US-5552285-A | DIAGNOSIS AND MONITORING OF INFLAMMATORY AND AUTOIMMUNE DISEASES | NEW YORK UNIVERSITY (US) | 1996-09-03 | — | — | US | claimed |
| EP-0706581-A1 | DNA PROFILES AS AN INDICATOR OF CELLULAR REDOX POTENTIAL AND CANCER RISK | PACIFIC NORTHWEST RESEARCH FOUNDATION (US) | 1996-04-17 | — | — | EP | claimed |
| US-5386030-A | Chemical intermediates | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCE OF THE CZECH REPUBLIC (CZ) | 1995-01-31 | — | — | US | claimed |
| EP-0630381-A4 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES. | — | 1995-01-04 | — | — | EP | claimed |
| EP-0630381-A1 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES. | ACAD OF SCIENCE CZECH REPUBLIC (CS) | 1994-12-28 | — | — | EP | claimed |
| WO-1994025626-A1 | DNA PROFILES AS AN INDICATOR OF CELLULAR REDOX POTENTIAL AND CANCER RISK | PACIFIC NORTHWEST RESEARCH FOUNDATION (US) | 1994-11-10 | — | — | WO | claimed |
| US-5208221-A | Nucleotides and intermediates for herpes virus or leukemia virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-05-04 | — | — | US | claimed |
| WO-1993007157-A1 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OFTHE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1993-04-15 | — | — | WO | claimed |
| WO-1992015707-A1 | IMMUNOASSAY FOR ANTIBODIES TO OXIDIZED DNA AND USES THEREOF | NEW YORK UNIVERSITY (US) | 1992-09-17 | — | — | WO | claimed |
| EP-0269947-A1 | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1988-06-08 | — | — | EP | claimed |